Huyabio International and BMS to collaborate on melanoma clinical

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Huyabio International and Bristol-Myers Squibb Co. are planning to evaluate the combination of Huyabio’s HBI-8000, an epigenetic immunomodifier, and Opdivo (nivolumab), a PD-1 blocking antibody.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

In recent months, several directors of cancer centers, appearing on The Directors, a segment of The Cancer Letter Podcast, mentioned that their institutions are increasingly providing small grants—typically in the range of $50,000—to scientists to enable them to keep their labs open.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login